Corcept Therapeutics
CORT
204 hedge funds and large institutions have $1.05B invested in Corcept Therapeutics in 2020 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 72 increasing their positions, 61 reducing their positions, and 35 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
97% more call options, than puts
Call options by funds: $6.79M | Put options by funds: $3.44M
18% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 61
6% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 35
0% less funds holding
Funds holding: 205 → 204 (-1)
0.81% less ownership
Funds ownership: 77.94% → 77.13% (-0.81%)
2% less capital invested
Capital invested by funds: $1.08B → $1.05B (-$26.8M)
Top Buyers
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$10.2M |
| 2 |
Renaissance Technologies
New York
|
+$6.62M |
| 3 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$6.28M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$6.16M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$5.99M |
Top Sellers
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$45.3M |
| 2 |
BlackRock
New York
|
-$8.36M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$7.23M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$5.92M |
| 5 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
-$4.69M |
CORT Hedge Fund Activity: Q1 2020 in Review
204 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q1 2020, worth a combined $1.05B — down 2.5% from $1.08B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new CORT positions and 35 closed out — a net gain of 2 holders — while 72 added to existing stakes and 61 trimmed.
The largest buyer was Deutsche Bank, adding an estimated $10.2M. The largest seller was Federated Hermes, cutting an estimated $45.3M.
- 204 institutional investors held Corcept Therapeutics (CORT) as of Q1 2020, down from 205 in Q4 2019.
- Funds reported $1.05B of Corcept Therapeutics stock for Q1 2020, down 2.5% quarter-over-quarter.
- 37 funds opened new Corcept Therapeutics positions in Q1 2020 and 35 closed out, a net change of +2 holders.
- The largest Corcept Therapeutics buyer in Q1 2020 was Deutsche Bank, an estimated $10.2M added.
- The largest Corcept Therapeutics seller in Q1 2020 was Federated Hermes, an estimated $45.3M sold.
Based on aggregated 13F filings for Q1 2020.